Cytoskeleton
proteins have been long recognized as structural
proteins that provide the necessary mechanical architecture for cell development and tissue homeostasis. With the completion of the
cancer genome project, scientists were surprised to learn that huge numbers of mutated genes are annotated as cytoskeletal or associated
proteins. Although most of these mutations are considered as passenger mutations during
cancer development and evolution, some genes show high mutation rates that can even determine clinical outcomes. In addition, (phospho)proteomics study confirms that many cytoskeleton-associated
proteins, e.g., β-
catenin, PIK3CA, and MB21D2, are important signaling mediators, further suggesting their biofunctional roles in
cancer development. With emerging evidence to indicate the involvement of mechanotransduction in stemness formation and cell differentiation, mutations in these key cytoskeleton components may change the physical/mechanical properties of the cells and determine the cell fate during
cancer development. In particular, tumor microenvironment remodeling triggered by such alterations has been known to play important roles in autophagy, metabolism,
cancer dormancy, and immune evasion. In this review paper, we will highlight the current understanding of how aberrant cytoskeleton networks affect
cancer behaviors and cellular functions through mechanotransduction.